IN8bio

IN8bio Quick Ratio

The Quick Ratio (Acid Test) of IN8bio (INAB) as of Oct 22, 2026 is 8.82. In the previous year, Quick Ratio (Acid Test) was 2.18 — a change of 305.10% (higher).

Quick Ratio

8.82

YoY

305.10%

Last updated:

Quick Ratio (Acid Test) of IN8bio is 2025 8.82 . Quick Ratio (Acid Test) of IN8bio was 2024 2.18 . It decreases by 305.10% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IN8bio Stock analysis

What does IN8bio do? IN8bio Inc is a clinical-stage biopharmaceutical company based in New York City, operating in the Health Care sector within the Biotechnology industry. The company develops novel therapies using allogeneic, autologous, and genetically modified gamma-delta T cells for treating cancers, including solid tumors and hematologic malignancies. With 26 employees, it focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates, currently advancing Phase 1 and Phase 2 clinical trials for glioblastoma and other cancer treatments. IN8bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IN8bio stock

Quick Ratio (Acid Test) of IN8bio is 8.82 in 2025.

Quick Ratio (Acid Test) of IN8bio changed from 2.18 to 8.82, representing a 305.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) IN8bio since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s IN8bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IN8bio

All Key Metrics — IN8bio